SSY Group advances innovative drug development programs

SSY Group Limited announced positive updates on its innovative drug development programs. Clinical trials for SYN045 tablets, a Type 1 new chemical drug targeting pulmonary hypertension, have shown promising results, with single and multiple administration studies completed successfully. The research demonstrated favorable human pharmacokinetic characteristics and improved safety and tolerability compared to similar drugs, potentially enabling long-term oral administration. SSY Group has filed 18 patents for the SYN045 project, including 5 international patents. Pending final Phase I results, the company plans to initiate Phase IIa trials. The Group is also progressing on an anti-epileptic drug targeting the KCNQ2/3 potassium ion channel and a pain treatment for anti-diabetic peripheral neuropathic pain, targeting the AAK1 protein kinase. Furthermore, research is underway to improve formulations of three new drugs, with two completing pharmacokinetic-based prescription studies.